Background: This work used mathematical modelling to explore effective policy for hepatitis C virus (HCV) treatment in Australia in the context of methadone maintenance treatment (MMT).
Introduction
Hepatitis C virus (HCV) is a significant cause of morbidity and mortality with an estimated 170 million people chronically infected globally (National Centre in HIV Epidemiology and Clinical Research, 2003) . Injecting drug use (IDU) is a major risk factor for HCV infection, and the majority of injecting drug users in virtually all nations are HCV positive (Lelutiu-Weinberger et al., 2009; National Centre in HIV Epidemiology and Clinical Research, 2007) . Between 70% and 90% of acute HCV cases progress to chronic infection (Guidotti and Chisari, 2006) . For those who receive treatment with pegylated interferon and ribavirin, approximately 50% will remain undetectable for HCV RNA 6 months post therapy (Novick and Kreek, 2008) . However, HCV treatment is unpleasant and not necessarily well tolerated (Novick and Kreek, 2008) . Moreover continued injecting behaviour places the user at risk of reinfection even if they successfully complete treatment (Aitken et al., 2008b) .
In these conditions, it is understandable that health practitioners may be reluctant to treat injecting drug users for HCV given concerns over poor compliance and the perceived risk of reinfection (Hopwood and Treloar, 2007; Sylvestre, 2005) . Both of these factors (compliance and risk of reinfection) can be significantly mitigated by methadone maintenance treatment (MMT) (Backmund et al., 2005) . Compliance with HCV treatment can be enhanced through the daily MMT contact with treatment personnel, in addition to enhancing the initial referral into HCV treatment. Risk of reinfection can be reduced if the methadone treatment successfully reduces or eliminates injecting and other risk behaviour. It is therefore of interest to explore the dynamics of HCV infection, treatment and reinfection in the context of a drug treatment program such as MMT.
This aim of this work was to use mathematical modelling to explore and draw some conclusions about effective policy for HCV treatment in the context of MMT and the likelihood of reinfection.
4
The extent to which all injecting drug users should receive treatment for Hepatitis C even if they continue to inject or engage in high risk behaviour is of policy interest because it will suggest how resources for HCV treatment could be distributed (between those in MMT and those outside MMT). It is also of ethical interest (Edlin et al., 2001) . Importantly, the high rates of movement into and out of MMT Chalmers et al., 2009) may mean that the putative advantages incurred by the MMT population in being treated for HCV may largely disappear.
Methods

The Single Group Model
We consider two mathematical models to depict HCV in the population of IDU. The first model considers the IDU population without separation into those that are or are not enrolled in MMT.
The model is depicted in Figure 1 where IDUs are separated into: the susceptible group , individuals that are injecting but not infected; the acutely infected group , individuals that have contracted HCV but have yet to pass to the chronic stage of the disease; the chronically infected group, ; the HCV treatment group ; and individuals who have recovered from HCV either spontaneously or through HCV treatment . Given the short period of acute infection, and that this frequently goes undetected, only chronically infected individuals were assumed to enrol in HCV treatment.
The governing equations for the first model are given in [1]
where N is the total of the IDU population
The terms in the first equation, which describe the rate of change in numbers of uninfected susceptible IDU, represent respectively: the influx of new users at rate per year, the uninfected users contracting HCV due to sharing with acutely and chronically infected individuals where , users that have lost immunity at rate after previously clearing the disease, and those IDUs in the susceptible group that exit the system due to cessation of risk behaviour or mortality at the rate , per year (this same exit rate also applies to all other groups).
The force of infection is the rate at which susceptible individuals become infected with HCV through exposure to infected users. The force of infection includes the probability that an uninfected individual will become infected when sharing with HCV-infected individuals over the course of a year . Its value is given by . The parameter is the number of days per year an IDU injects and shares, and p denotes the probability of getting infected each day of injecting and sharing, if sharing is with an HCV infected individual. The infection rate is multiplied by the proportion of infectious individuals in the total population reflecting the probability of having contact with an infected individual.
Other terms of note are the terms and , which represent those users infected with the disease that either spontaneously recover at the rate per year or pass to the chronic stage at the rate per year and the terms and , which represent those users that have entered treatment and succeed in clearing the disease with probability or have failed treatment with probability . In both cases, these users leave HCV treatment at the respective rates and per year.
We consider the rate at which HCV infected IDUs enter treatment to be dependent on the total population given by the treatment function 
The Two Group Model with MMT
The second model separates the IDU population depending on whether individuals are enrolled in MMT. We duplicate the structure of the Single Group model for individuals in MMT (subscript M), and those not in MMT (subscript N). Users are assumed to be able to move between each group at rates , the rate at which users move into MMT and the rate at which users leave
.
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MMT. The dynamics of the Two Group model are altered by two factors: 1) the rate of enrolment in MMT and 2) the relative likelihood of infection due to injecting risk behaviour ( ).
The force of infection for users not in MMT is given by,
and for those in MMT treatment, 
Parameter Estimation
We estimated parameters for the models based on IDU and HCV observations in Australia.
These estimates are summarised in Table 1 . The estimated number of new IDUs per year , is 4500 (Chalmers et al., 2009 ). The spontaneous recovery rate, , and the progression rate to chronic infection , can be estimated from observations that 25% of all HCV infected individuals clear infection within the first 6 months with the remainder progressing to chronic infection (Micallef et al., 2006; Razali et al., 2007) . So we assume an average time in the acute state , to be 6 months for all individuals. A distinction must be made between those acutely and chronically infected IDUs to take into account the approximately 25% of those infected that clear the virus without treatment (Guidotti and Chisari, 2006) . The annual rate of spontaneous recovery is then estimated as the inverse of the time in acute infection (in years) times the probability an individual clears infection (25%) which gives per year. The chronic progression rate , is similarly estimated from the inverse of the time in acute infection times the probability an individual fails to clear infection 75%. This leads to the parameter estimate (year -1 ).
In Australia, the annual HCV treatment rate is around 1% (Matthews, 2005) . The length of HCV treatment is 24 weeks for Genotypes 2 and 3 and 48 weeks for Genotype 1 (Novick and Kreek, 2008; Ostapowicz et al., 1999) . Hence we assume an average length of treatment of 36 weeks.
We assume that if HCV treatment is successful the patient will stay for the entire course, and that those not successful adhere only half as well, so treatment is for an average period of 18 weeks (Ostapowicz et al., 1999) . This leads to the rate of those failing HCV treatment of 52/18 per year and the rate for is 52/36 per year. The probability of success of HCV treatment is approximately 50% (Novick and Kreek, 2008) .
HCV prevalence among IDUs in Australia is approximately 60% (National Centre in HIV Epidemiology and Clinical Research, 2007, 2008) . We take an estimate of incidence to be 20%
per year (Matthews, 2005; Micallef et al., 2006) . This is likely to be an overestimate, but is somewhat accommodated by our under-estimate of reinfection rate (see below). The number of new infections per year is therefore given by so that per year. There is debate about the rate of reinfection in those that have previously cleared infection with estimates ranging from 2% to 47% per year (Aitken et al., 2008a; Backmund et al., 2004; Grebely et al., 2006) . We assume a reinfection rate, of 5% per year thus but acknowledge that new research suggests it is higher than this.
The exit rate , was determined from fitting the steady state prevalence, of 60%.
Assuming that current endemic steady state corresponds to the situation of 1% of the population of IDUs being treated for HCV ( =0.01) we estimate the exit rate to be roughly 0.083 per year.
For the Two Group model, we assume that most of the parameters are the same as those for the Single Group model, with the exception being the infection rate . We do not assume zero injecting whilst in MMT. We use data from Australian clinical trials on the number of days injecting out of MMT and within MMT: those within MMT on average inject approximately 8 fold less than those not enrolled in a program (Mattick et al., 2001; Moore et al., 2007; Teesson et al., 2006) . 
Sensitivity Analyses
Results described below are robust to parameter choices (Table 1 ). Sensitivity analyses revealed that the parameters that had the largest impact on steady state HCV prevalence were the rate of infection , and the exit rate , where changing these by resulted in a 4-6% change in the predicted prevalence. There was a smaller 3% change associated with the clearance probability . Perturbations of all other parameters by , resulted in changes in steady state HCV prevalence of less that 1%. The sensitivity analysis for the Two Group model also determined that the infection rate of the non-methadone treatment group, , and the exit rate (when varied equally between the groups), , had the largest effect on the predicted steady state prevalence (4-6%).
Results
Single Group Model
Initially we consider the IDU population as a whole, without separation into whether individuals are enrolled in MMT or not. In this instance we investigate, on average, the impact on eventual HCV prevalence of increasing levels of HCV treatment. The eventual prevalence is determined from the steady state value of the mathematical model, and we denote outcomes in terms of these steady state values. Of particular interest is the extent to which reinfection, for those that clear the infection either spontaneously or after successful HCV treatment, will negate any decreases in expected levels of HCV prevalence with expanded HCV treatment. The risk of HCV reinfection for active drug users has been one of the reasons promulgated for not providing HCV treatment to these individuals (Aitken et al., 2008b; Sylvestre, 2005) .
At current HCV treatment levels (1% of IDU, (Matthews, 2005 Although this critical treatment level eventually eliminates infection, it is slow to do so taking 3.3 years for chronically infected numbers to decrease by half and 11.1 years for acute numbers to halve. Implementing this critical treatment level of 56.5% from current levels where HCV prevalence is 60%, and the majority of these in the chronic stage, would mean that initially 56.5% of 60% so 33.9% of IDUs would be enrolled in HCV treatment. However as HCV treatment decreases prevalence, this treatment burden also decreases so that after 3 years when chronically infected numbers have halved, then the percentage enrolled in treatment at that time will also halve to 17%.
The ability to eliminate HCV prevalence with suitably high levels of HCV treatment is calculated on parameter levels that duplicate the situation within Australia. It is dependent on rates of needle sharing, contained within the infection term , and this must be less than the rates at which acutely infected individuals leave this compartment, Since , if sharing is higher than this then no amount of testing and treatment will eradicate HCV infection.
The Two Group model: the impact of MMT
The previous analysis investigated the impact of increasing levels of HCV treatment on This optimal allocation shifts between groups as levels of HCV treatment increase from their current 1% (Figure 4) . At current treatment levels all therapy should be targeted to those not in MMT, but with increasing levels of HCV treatment a portion of this shifts to those enrolled in MMT (Figure 4 ). For the critical treatment level that theoretically eliminates HCV, the optimal allocation is approximately 15% to those in MMT and the vast majority 85% to those not in MMT.
In the previous calculations the only difference assumed between the two groups is that those in MMT are less likely to inject and share, and are therefore less likely to become HCV-infected.
However achievement of a sustained virological response has been associated with less frequent drug use (Sylvestre, 2005) . There is some debate about whether MMT increases compliance with HCV treatment (Ebner et al., 2009; Novick and Kreek, 2008; Treloar and Fraser, in press ). Therefore, if we assume that those not in MMT are less adherent to HCVtreatment resulting in lower probability of success for this group ( ), then the optimal allocation point shifts to favour those in MMT. For the case of 50% treatment of all IDU, if those in the non-MMT group are only 48% as adherent to HCV therapy as those in MMT then allocation of HCV testing becomes equally distributed between groups. However even at this point there will be more individuals treated, rather than just tested, for HCV given the higher HCV prevalence in the non-MMT group. Of the model value of 33,227 individuals not in MMT,
13,550 will be tested and the 2,090 of these who have chronic HCV will be treated. On the other hand only 1,919 MMT individuals will have chronic HCV and be treated.
Numbers entered into HCV therapy in each group will be the same (2,067 individuals) if adherence to HCV therapy in the non MMT group is only 44.3% of that in the MMT group. If adherence to HCV therapy in the non MMT group falls below 44.3% of that in the MMT group then the number tested and treated should be preferentially directed to those in MMT.
Discussion and Conclusions
Although increasing HCV treatment can lead to a relatively large decrease in chronically HCVinfected IDU, HCV reinfection significantly impacts on the success of HCV treatment. The numbers acutely infected decay at a slow rate, as those that have previously been chronically infected re-enter the susceptible pool and become infected again. Contrary to expectations this results in higher levels of acute infection for small increases in treatment level.
We have assumed that unlike human immunodeficiency virus (HIV) (Yerly et al., 2001) , where viral loads are highest, acute HCV infection is not more infectious than chronic stage disease.
Although viral loads are generally highest at acute HCV infection (Herring et al., 2005; Thimme et al., 2001) , they generally do not experience a 100-fold decrease to chronic infection as seen in HIV (Murray et al., 1998) . However if acute HCV infection is more infectious than chronic stage disease then it will exacerbate the rise in numbers acutely infected IDU when treatment increases, and will further slow the time taken to reduce HCV prevalence.
Those acutely infected were included separately in the models since they can experience spontaneous clearance of HCV infection (Micallef et al., 2006) higher rates of sustained virological response (Santantonio et al., 2008) . Given that acute HCV infections are more likely to occur in individuals not enrolled in MMT, including the acute group in HCV treatment would further shift the preference towards the non-MMT group, although the change would not be substantial, given the difficulty in identifying this group.
When HCV treatment is sufficiently high, approximately 60%, these models predict that HCV can be eliminated. Regardless of whether this is realistically feasible, our calculations underline the importance of programs that minimise the sharing of infected needles. If sharing is not effectively constrained, then no level of HCV treatment will be able to eliminate the epidemic, even in this simple theoretical setting. It emphasises the role that Needle Syringe Programs have had in containing HIV levels in Australian IDU, and in keeping HCV prevalence, although still high, at levels lower than other communities that have not invested as heavily in prevention (Murray et al., 2003) . It also stresses that any push to expand HCV treatment must not be at the expense of preventative measures.
It is difficult to accurately determine the rate of cycling in and out of MMT. While we use recent published estimates, these are averages across diverse populations and indeed, little is known about the rates of entry and exit and lengths of stay in MMT in Australia, because most research measures the proportion remaining in treatment at certain time points (3, 6 and 12 months).
These do not easily convert to estimated duration in or out of MMT. We use population parameters of IDU, which are not necessarily heroin only (ie people inject amphetamines and are at risk of HCV infection through any injecting behaviour, not just opioids), and a treatment that is only for heroin (MMT).
Notwithstanding all these limitations, many of which are normal in the course of mathematical modelling (eg (Razali et al., 2007) , this work represents the beginning of opportunities to explore, through mathematical modelling, ways in which policy on HCV treatment can be improved. Including more aspects of practical HCV treatment in a population over the long term, such as the spread of drug resistant virus and the impact of new treatment options such as HCV protease inhibitors, will be important components for the future. Although our model is simple, both in terms of the drug treatment (represented by MMT) and in terms of reinfection rate, it reveals some important potential policy implications: that we should be focusing our efforts on treating those with HCV in the community who continue to inject is perhaps at least a counterintuitive finding. Improved compliance with HCV therapy for those in MMT would need to be high to counteract our finding. Outcome studies are required to derive effect sizes on adherence and therapy success rates. Future models could then use these, providing greater precision in determining the optimal HCV therapy allocation. Changes to these important parameters (adherence, methadone turnover rates, HCV therapy outcomes) may lead to alternate conclusions from those derived here and may confer greater policy relevance to treating those within MMT over those in the community.
The preferential targeting of HCV treatment to those not in MMT is partially a result of the continual recycling of IDUs in and out of MMT. Calculations with longer duration in MMT shift the optimal HCV treatment allocation more to those in MMT. So any measures that can lead to more sustained MMT will have a double effect: it will reduce the likelihood than an individual will continue to inject, and it will offer greater effectiveness of any HCV treatment. Especially if adherence is greater for those in MMT, retention of individuals in MMT can provide a multiplier effect on HCV treatment. Our results of the high proportion of HCV treatment targeted to individuals who continue to inject may reflect the poor retention and cycling behaviour of patients within MMT rather than any inherent benefit of targeting active IDUs. participants.
